Penumbra (PEN) Competitors

Penumbra (NYSE:PEN) and Zimmer Biomet (NYSE:ZBH) are both medical companies, but which is the better investment? We will contrast the two businesses based on the strength of their analyst recommendations, valuation, earnings, community ranking, media sentiment, profitability, dividends, risk and institutional ownership.

Do analysts recommend PEN or ZBH?

Penumbra presently has a consensus target price of $258.00, suggesting a potential upside of 6.37%. Zimmer Biomet has a consensus target price of $123.33, suggesting a potential upside of 15.14%. Given Zimmer Biomet's higher possible upside, analysts plainly believe Zimmer Biomet is more favorable than Penumbra.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Penumbra	0 Sell rating(s)	4 Hold rating(s)	10 Buy rating(s)	1 Strong Buy rating(s)	2.80
Zimmer Biomet	2 Sell rating(s)	11 Hold rating(s)	7 Buy rating(s)	0 Strong Buy rating(s)	2.25

Which has more volatility & risk, PEN or ZBH?

Penumbra has a beta of 0.51, meaning that its share price is 49% less volatile than the S&P 500. Comparatively, Zimmer Biomet has a beta of 1.02, meaning that its share price is 2% more volatile than the S&P 500.

Is PEN or ZBH more profitable?

Zimmer Biomet has a net margin of 14.27% compared to Penumbra's net margin of 2.97%. Zimmer Biomet's return on equity of 12.95% beat Penumbra's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Penumbra	2.97%	8.99%	6.80%
Zimmer Biomet	14.27%	12.95%	7.55%

Do institutionals and insiders hold more shares of PEN or ZBH?

88.9% of Penumbra shares are held by institutional investors. Comparatively, 88.9% of Zimmer Biomet shares are held by institutional investors. 5.0% of Penumbra shares are held by company insiders. Comparatively, 1.0% of Zimmer Biomet shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company is poised for long-term growth.

Does the MarketBeat Community believe in PEN or ZBH?

Zimmer Biomet received 81 more outperform votes than Penumbra when rated by MarketBeat users. However, 80.29% of users gave Penumbra an outperform vote while only 67.16% of users gave Zimmer Biomet an outperform vote.

Company	Underperform	Outperform
Penumbra	Outperform Votes 819 80.29%	Underperform Votes 201 19.71%
Zimmer Biomet	Outperform Votes 900 67.16%	Underperform Votes 440 32.84%

Which has better valuation & earnings, PEN or ZBH?

Zimmer Biomet has higher revenue and earnings than Penumbra. Zimmer Biomet is trading at a lower price-to-earnings ratio than Penumbra, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Penumbra	$1.16B	8.00	$90.95M	$0.86	282.02
Zimmer Biomet	$7.60B	2.81	$1.02B	$5.26	20.37

Does the media prefer PEN or ZBH?

In the previous week, Zimmer Biomet had 1 more articles in the media than Penumbra. MarketBeat recorded 15 mentions for Zimmer Biomet and 14 mentions for Penumbra. Penumbra's average media sentiment score of 0.86 beat Zimmer Biomet's score of 0.84 indicating that Penumbra is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Penumbra	6 Very Positive mention(s)	1 Positive mention(s)	5 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Zimmer Biomet	4 Very Positive mention(s)	2 Positive mention(s)	4 Neutral mention(s)	2 Negative mention(s)	0 Very Negative mention(s)	Positive

Summary

Zimmer Biomet beats Penumbra on 11 of the 19 factors compared between the two stocks.